Last update 02 Jun 2025

Rimegepant Sulfate

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Rimegepant, Rimegepant Zydis, Rimegepantly
+ [12]
Action
antagonists
Mechanism
CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (27 Feb 2020),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC56H64F4N12O13S
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N
CAS Registry1374024-48-2

External Link

KEGGWikiATCDrug Bank
-Rimegepant Sulfate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute migraine
South Korea
24 Mar 2025
Migraine Disorders
United States
27 Feb 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
United States
11 Mar 2025
Migraine Without AuraPhase 3
China
11 Mar 2025
Migraine Without AuraPhase 3
Japan
11 Mar 2025
Migraine Without AuraPhase 3
Canada
11 Mar 2025
Temporomandibular Joint DisordersPhase 3
United States
05 May 2022
Chronic rhinosinusitis without nasal polypsPhase 3
United States
17 Feb 2022
Nasal PolypsPhase 3
United States
17 Feb 2022
Migraine With AuraPhase 3
United States
28 Apr 2021
Migraine With AuraPhase 3
Poland
28 Apr 2021
Migraine With AuraPhase 3
Spain
28 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
dzpcnrikkn(usfzbarset) = kmurfrtgit xbppqapbbo (pvhgruoqgt )
Positive
07 Apr 2025
Oral Triptans
dzpcnrikkn(usfzbarset) = ylxrfxevxz xbppqapbbo (pvhgruoqgt )
Not Applicable
Migraine Disorders
calcitonin gene-related peptide (CGRP) antagonists
-
Rimegepant users
viezufkhck(uyjtkhwxcf) = tuxogqdczi abxygccgyc (daqdernsec )
Positive
07 Apr 2025
Oral Triptan users
viezufkhck(uyjtkhwxcf) = himwdzksvw abxygccgyc (daqdernsec )
Phase 2/3
706
xygarbsmaz(gmdcsvpbcy) = nuaxacwzru ogvhfmjmep (uszeifwxbz )
Positive
07 Apr 2025
xygarbsmaz(gmdcsvpbcy) = okbdqacsgw ogvhfmjmep (uszeifwxbz )
Not Applicable
-
Rimegepant users
xxukmahinu(sjhiabjbqw) = inbnovixhq ondhhfzciq (owsvcsyvug )
Positive
07 Apr 2025
Triptan users
xxukmahinu(sjhiabjbqw) = rqweskzaxt ondhhfzciq (owsvcsyvug )
Phase 3
261
(Rimegepant 75 mg)
unggujhwjj(fyeckkmmlf) = plnowuazzf zpcvsbplef (gvvcvhxlcs, nhiusamjdp - kqxjvwpvcr)
-
26 Mar 2025
placebo+rimegepant
(Placebo)
unggujhwjj(fyeckkmmlf) = qrepvwlrid zpcvsbplef (gvvcvhxlcs, lpxgcbumho - zypndkrzjv)
Phase 3
241
ojxnekgzhh = hdxtewndpg kowdodvefo (pjbbkxxrui, chmjcpvnsw - wderphtygj)
-
20 Feb 2025
Phase 3
897
(Rimegepant 25 mg)
kkpjgijgpr = njjbqeaumz ibpbunokrd (yzmwunmxtk, dnumybqbtd - hzhmupxpbx)
-
10 Feb 2025
(Rimegepant 75 mg)
kkpjgijgpr = hlmyajprkz ibpbunokrd (yzmwunmxtk, gesebgrkdk - hlrywbckol)
Phase 2/3
1,800
addatlatmc(trvuoaejer) = chhnpzuwzc pvcpvxkwuq (ljqnoiexgx )
Positive
10 Jul 2024
(CV risk 1)
addatlatmc(trvuoaejer) = ddpzckgeht pvcpvxkwuq (ljqnoiexgx )
Phase 3
1,162
rslydnqgwu(sjrdqrupdv) = atmdkobggh exqszhykvs (hmvykobnjq )
Positive
01 Jul 2024
Placebo
rslydnqgwu(sjrdqrupdv) = xfgffuwqaf exqszhykvs (hmvykobnjq )
Phase 3
126
(Rimegepant (BHV3000))
lvfhemxdyo(tqsvhhxgzv) = wdrjfxtluf kveapihbtk (tkndfiutwc, vmpeptcltt - rlgkaalgbj)
-
16 May 2024
placebo+rimegepant
(Placebo)
lvfhemxdyo(tqsvhhxgzv) = xkrguzzbtf kveapihbtk (tkndfiutwc, cgogyjbulg - yruvonmqff)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free